This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why You Might Swap Your Merck for Johnson & Johnson

NEW YORK ( TheStreet) -- Sometimes when an investor wants exposure to the pharmaceutical and health care sector it's better to buy an exchange-traded fund for the sake of diversity.

Many want to own the best-in-breed or, more specifically, the best-in-the-sector. Yet, what if you're already invested in two of the great ones like Pfizer (PFE) and Merck (MRK - Get Report)?

Your asset allocation strategy may say it's time to sell one and use that cash to buy the Big Kahuna of drugmakers, over-the-counter remedies, medical products and other related consumer goodies.

I'm referring to Johnson & Johnson (JNJ - Get Report). With a market cap of more than $246 billion, it's arguably the world's largest health care company.

JNJ has three divisions: pharmaceutical, medical devices, and diagnostics and consumer. Pharmaceutical accounts for 38% of the company's revenue and has been the highlight because of its strong pipeline, especially in oncology and immunology, which helped to drive 12% revenue growth in the second quarter.

Jim Cramer and Stephanie Link at Action Alerts PLUS wrote on Friday, "We see continued strength in these two segments [oncology and immunology], but we also believe the company is well positioned for the long term with pipeline opportunities in treatments for cancer, pain, schizophrenia, hepatitis C and HIV."

They also commented that during the second quarter, immunology sales rose by nearly 17% "... driven by strong Remicade sales of 9.8% and solid results from Simponi and Stelara.

"We expect this strength to continue, given the growth in the overall market, expansion into international markets (emerging markets grew 20% in the second quarter) and share gains."

Investors who acted upon their past preference for Merck did quite well when it came to total returns, which included MRK's dividend. The stock peaked on June 4 at $50.16 and has corrected.

MRK is currently selling at a forward (one-year) PE ratio of slightly less than 13. Its price-to-earnings-growth (PEG) ratio (five-year expected) is an unusually high 5.02 which could signal shares are overvalued.

Presently I'd favor JNJ over MRK for the same reasons Cramer and Link do: "We prefer it [JNJ] to Merck, given its stronger growth and better pipeline, and we like the potential for shareholder value creation, which ultimately led to a spin-out of its consumer segment."
1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
JNJ $98.44 0.00%
MRK $57.67 0.00%
AAPL $126.44 0.00%
FB $87.28 0.00%
GOOG $523.40 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs